TW202400158A - 以μ-阿片受體拮抗劑治療癌症及其他病症的方法 - Google Patents

以μ-阿片受體拮抗劑治療癌症及其他病症的方法 Download PDF

Info

Publication number
TW202400158A
TW202400158A TW112108783A TW112108783A TW202400158A TW 202400158 A TW202400158 A TW 202400158A TW 112108783 A TW112108783 A TW 112108783A TW 112108783 A TW112108783 A TW 112108783A TW 202400158 A TW202400158 A TW 202400158A
Authority
TW
Taiwan
Prior art keywords
cancer
mor antagonist
mor
inhibitor
antagonist
Prior art date
Application number
TW112108783A
Other languages
English (en)
Chinese (zh)
Inventor
羅琳 強森
強納森 摩斯
大衛 塔格特
Original Assignee
美商葛萊希克斯莫爾公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商葛萊希克斯莫爾公司 filed Critical 美商葛萊希克斯莫爾公司
Publication of TW202400158A publication Critical patent/TW202400158A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW112108783A 2022-03-10 2023-03-09 以μ-阿片受體拮抗劑治療癌症及其他病症的方法 TW202400158A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263318465P 2022-03-10 2022-03-10
US63/318,465 2022-03-10

Publications (1)

Publication Number Publication Date
TW202400158A true TW202400158A (zh) 2024-01-01

Family

ID=87936037

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112108783A TW202400158A (zh) 2022-03-10 2023-03-09 以μ-阿片受體拮抗劑治療癌症及其他病症的方法

Country Status (10)

Country Link
US (1) US20250186423A1 (https=)
EP (1) EP4489866A4 (https=)
JP (1) JP2025508131A (https=)
KR (1) KR20250004644A (https=)
CN (1) CN119584986A (https=)
AU (1) AU2023231655A1 (https=)
CA (1) CA3253916A1 (https=)
IL (1) IL315501A (https=)
TW (1) TW202400158A (https=)
WO (1) WO2023173055A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
WO2025137697A1 (en) * 2023-12-21 2025-06-26 Glycyx Mor Inc. Methods, systems, and compositions related to use of mu opioid receptor (mor) antagonists
CN121534059A (zh) * 2024-08-09 2026-02-17 盐野义有限公司 一种治疗帕金森综合征或帕金森病的方法和药物组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524731B2 (en) * 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
ES2714198T3 (es) * 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
JP6686013B2 (ja) * 2014-10-17 2020-04-22 サリックス ファーマスーティカルズ，インコーポレーテッド 腫瘍の進行を減弱させるためのメチルナルトレキソンの使用
EP3490542A4 (en) * 2016-07-26 2020-07-08 Flagship Pioneering Innovations V, Inc. NEUROMODULATION COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATION OF AN ANTI-CANCER RESPONSE
US12053523B2 (en) * 2017-12-13 2024-08-06 North Carolina State University Compositions comprising chemotherapeutic agents and checkpoint inhibitors and methods of use
US11471459B2 (en) * 2018-03-26 2022-10-18 Fondazione Per L'istituto Oncologico Di Ricerca (Ior) Compounds with enhanced anti-tumor effects
US20220125844A1 (en) * 2020-10-23 2022-04-28 The Johns Hopkins University Opioid antagonists for use in patients using chimeric antigen receptor t and natural killer (nk) cell therapy

Also Published As

Publication number Publication date
JP2025508131A (ja) 2025-03-21
EP4489866A2 (en) 2025-01-15
CN119584986A (zh) 2025-03-07
KR20250004644A (ko) 2025-01-08
IL315501A (en) 2024-11-01
WO2023173055A2 (en) 2023-09-14
US20250186423A1 (en) 2025-06-12
AU2023231655A1 (en) 2024-10-17
EP4489866A4 (en) 2026-03-11
CA3253916A1 (en) 2023-09-14
WO2023173055A3 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
TW202400158A (zh) 以μ-阿片受體拮抗劑治療癌症及其他病症的方法
JP6411523B2 (ja) プリナブリン及びタキサンの組合せがん治療
TWI386203B (zh) 治療腦癌或用以降低腦癌細胞對替莫唑胺之抗藥性之醫藥組合物及其應用
JP7001599B2 (ja) 急性骨髄性白血病の処置のためのダクチノマイシン組成物および方法
CN103635187A (zh) 用于抑制化疗引起的副作用的药物治疗以及相关药物组合物、诊断试剂、筛选技术和试剂盒
KR20130140032A (ko) 암을 치료하는 방법들
US20250090514A1 (en) Method of treating cancer
WO2020180534A1 (en) Methods and compositions for protein delivery
US11000518B2 (en) Use of combination of VEGFR inhibitor and PARP inhibitor in preparation of medicament for treating gastric cancer
WO2020123582A1 (en) Cxcr7 inhibitors for the treatment of cancer
KR101901001B1 (ko) PPAR-β 길항제를 포함하는 항암 효과 증진용 약학적 조성물
US20250186393A1 (en) Treatment of breast cancer with amcenestrant
TW202423403A (zh) 一種治療前列腺癌的藥物組合及其應用
CN111565719A (zh) 用于治疗食管癌的crac通道调节剂
EP4663191A1 (en) Use of tyrosine kinase inhibitor
CN116236477B (zh) 溶血磷脂酸受体5拮抗剂在制备心脏保护药物中的应用
WO2020243058A1 (en) Compositions and methods to treat cancer
CN116327772B (zh) SMO抑制剂Sonidegib对管腔型乳腺癌骨转移的靶向治疗方法
WO2011139867A2 (en) Method of treating brain cancer
KR20190019489A (ko) Rip3 발현 촉진제 또는 활성화제를 포함하는 항암 보조용 조성물
JP2026500734A (ja) 医薬組み合わせ、及びその使用
WO2024102968A1 (en) Uses of ep2/ep4 antagonist compounds for treating familial adenomatous polyposis (fap)
WO2020205608A1 (en) Uses of androgen receptor antagonists and jnk pathway inhibitors, and pharmaceutical compositions related thereto
WO2022081521A1 (en) Inositol-bispyrophosphate-derived compounds and uses thereof